Brea C. Lipe, MD explains common grade 3 and grade 4 adverse events observed in the PERSEUS trial.
Summary
In terms of safety, the PERSEUS trial did not reveal any new or unexpected adverse events. The most common side effects were thrombocytopenia and neutropenia, consistent with the known safety profile of Dara-VRd which tends to have higher rates of cytopenia compared to VRd alone. Notably, this trial was conducted during the COVID-19 pandemic. Higher rates of infectious complications like pneumonia were seen in the Dara-VRd arm compared to VRd alone. This reinforces our understanding that quadruplets can increase susceptibility to infections, though we are learning how to better mitigate these risks. Overall, the safety profile aligned with expectations for Dara-VRD, with managing cytopenia and infections as key considerations.
Summary was AI-generated and edited for clarity.
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More
Age, Disease Burden Are Factors in Early Use of Selinexor in Multiple Myeloma
April 22nd 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed treatment approaches and the tolerability of a selinexor-containing regimen in a patient with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More